GLP1R and type 1 diabetes mellitus: Patients with T1DM report initiating adjuvant treatment with GLP‐1 RA and/or SGLT2i to improve glycaemic control and lose weight; most patients reported perceived benefits from these therapies. Side effects (including DKA) are reported more commonly in real life than in clinical trials.